OBJECTIVE: To assess the impact of primary HIV infection (PHI) on the spread of HIV and the temporal trends in transmission of HIV drug resistance between 1996 and 1999 in Switzerland. METHODS: Sequencing of the genes for reverse transcriptase (RT) and protease was performed for 197 individuals with documented PHI. Phylogenetic analyses were confronted with epidemiological data. RESULTS: Significant clustering was demonstrated for 29% of the RT sequences. All these cases occurred closely together in place and time; contact tracing demonstrated transmission at the time of PHI in 30% of them. Genotypic drug resistance was detected in 8.6% of PHI individuals in 1996, 14.6% in 1997, 8.8% in 1998 and 5.0% in 1999. Drug-resistant variants were id...
BACKGROUND: Sequence data from resistance testing offer unique opportunities to characterize the str...
Transmission of drug-resistant variants is influenced by several factors, including the prevalence o...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVE: To assess the impact of primary HIV infection (PHI) on the spread of HIV and the temporal...
OBJECTIVES: To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with lar...
OBJECTIVES: To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with lar...
OBJECTIVES: Representative prevalence data of transmitted drug-resistant HIV-1 are essential to esta...
OBJECTIVES: Representative prevalence data of transmitted drug-resistant HIV-1 are essential to esta...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compro...
Transmission of drug-resistant variants is influenced by several factors, including the prevalence o...
Background. Sequence data from resistance testing offer unique opportunities to characterize the str...
Background. Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compro...
BACKGROUND: Sequence data from resistance testing offer unique opportunities to characterize the str...
Transmission of drug-resistant variants is influenced by several factors, including the prevalence o...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVE: To assess the impact of primary HIV infection (PHI) on the spread of HIV and the temporal...
OBJECTIVES: To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with lar...
OBJECTIVES: To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with lar...
OBJECTIVES: Representative prevalence data of transmitted drug-resistant HIV-1 are essential to esta...
OBJECTIVES: Representative prevalence data of transmitted drug-resistant HIV-1 are essential to esta...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) ...
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compro...
Transmission of drug-resistant variants is influenced by several factors, including the prevalence o...
Background. Sequence data from resistance testing offer unique opportunities to characterize the str...
Background. Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compro...
BACKGROUND: Sequence data from resistance testing offer unique opportunities to characterize the str...
Transmission of drug-resistant variants is influenced by several factors, including the prevalence o...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...